GBIO Generation Bio Corp: Operating Profitability

Generation Bio Co. - graphic logo of issuer GBIO

Generation Bio Co. (GBIO) is developing non-viral DNA delivery methods for the treatment of eye and liver pathologies. Future revenues are based on the commercialization of the ceDNA platform, which enables repeated treatment of genetic diseases. The company is currently in the pre-commercial stage, meaning external financing only serves to mitigate capital expenditure. The quarterly operating margin clearly demonstrates efficiency trends, where the value of -512.50 expresses the metric level.

GBIO - Generation Bio Co Operating Profit Rate over the range 07/04/2022 - 02/21/2026

Metric breakdowns and analytics for Generation Bio Co. (GBIO)

- share price and consensus valuation forecast:
Initial company analysis:Generation Bio, GBIO
Core merchandise of Generation Bio Corp

For Generation Bio Co. (GBIO), which protects its unique DNA platforms with patents, the negative margin reflects a stage of capital-intensive development under strict FDA oversight. An analysis of operating profit margins allows for an assessment of the operating income share after deducting all expenses, excluding the impact of debt load and taxes, which confirms the strategic priority of scaling technologies over current profitability.

Competitors of Generation Bio Co. (GBIO)

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations Stoke Therapeutics|Operating Profitability BioLife Solutions BLFS|Wave Life Sciences (WVE) - Operating Return on Sales|Maze Therapeutics, Inc. - Operating Margin|Profitability of Operations Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operating Profitability|TSHA: Operating Profit Ratio|Operating Profitability uniQure Pharma|MGTX - Operating Profitability Margin|Operating Margin RGNX|Operating Profitability SLDB (Solid Biosciences)|Ocugen Corp - Operating Sales Margin|PACB: Return on Sales by Operating Profit|benitec.com - Operating Margin|DSGN - Operating Margin|RCKT: Operating Margin|FDMT (4D Molecular Therapeutics Inc) - Operating Profitability|Operating Sales Margin LXEO|Operating Profitability KRRO|Operating Margin EDIT|SLN - Operating Return on Sales|Operating Margin PRQR (ProQR)|CDXS - Operating Sales Margin|Sangamo Therapeutics Inc. - Operating Margin|NAUT - Operating Margin|MGX: Operating Margin|Operating Sales Margin Precision BioSciences, Inc.|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability